Diabetes

The American Academy of Neurology recently issued a guideline on oral and topical treatments for painful diabetic neuropathy. Here, a concise summary for clinicians.

Glucose and insulin levels decreased after just 3 minutes of the moderate-intensity exercise, a promising finding for those with type 2 diabetes, say authors of a new study.

Coronary heart disease prevalence in the US between 2011 and 2018 saw a statistically insignificant change, from 6.2% to 6.0%, respectively.

Use of continuous glucose monitoring to assess time in target glucose range in T2D patients was evaluated in a systematic literature review covering ~14 000 participants.

Available therapies combined with new approaches that address social determinants of health and other barriers to care can help, suggests new statement.

WATCH: The FDA approval of semaglutide 2.4 mg for adults with obesity was "by far the big event in 2021," said Donna Ryan, MD. More from our look back/look ahead interview, here.

The ADA's annual update to its comprehensive evidence-based standards includes new guidance on diabetes screening, first-line therapies, and comorbid NAFLD/NASH.

CGMs have revolutionized diabetes management for patients and healthcare providers alike. This slide show summarizes the most recent enhancements.

Continuous glucose monitoring for type 2 diabetes patients is gaining exposure in the literature with positive evidence accumulating. Examples follow.

While use of insulin pumps and CGM increased over a 3-year study period for all racial-ethnic groups, the inequities were significant between White adults and all others.

Finerenone, the nonsteroidal mineralocorticoid receptor antagonist, significantly reduced new-onset HF and improved other HF outcomes in the FIGARO-DKD trial.

Increases in obesity parameters significantly increased risk of incident heart failure in persons with diabetes, but not without diabetes, in a large community-based cohort study.

Get a quick look at 12 of the many FDA-approved drugs in 2021 for conditions commonly seen in primary care.

ADA 2021 Scientific Sessions recap, tests of clinical knowledge, expert interviews, and more in this roundup from Patient Care Online.

Weight loss and disease remission in T2D may differ between patients regardless of type of diet regimen chosen, say authors of a new analysis.

AHA 2021. Heart failure patients, across ejection fraction and diabetes status, reported improved QOL as early as 3 months in CHIEF-HF trial.

Finerenone was associated with a 20% lower risk of end-stage kidney disease among patients with T2D and CKD, according to authors of the FIDELITY analysis.

For individuals with A1c of 6.4-6.5%, just below the threshold for diabetes, risk of MACE was higher than for any other subgroup with A1c values ranging from 5.8-6.8%.

Among patients with diabetes, over 50% of statin users experienced diabetes progression vs 48% of non-statin users, according to a retrospective matched-cohort study.

EASD 2021: Patients with metabolically healthy obesity are nearly 33% more likely to develop heart failure and atrial fibrillation than healthy persons of normal weight, suggests new analysis.

EASD 2021: First analysis of its kind found COVID-19-induced lockdown was associated with improved glycemic control among patients with T1D, but not T2D.

This post-hoc analysis showed increased reductions in A1c, weight, and BP in T2D patients prescribed GLP-1 receptor agonists who were already taking an SGLT-2 inhibitor.

A pattern of nocturnal reverse-dipping blood pressure in persons with type 1 or 2 diabetes put them at more than twice the risk of all-cause mortality, according to new research.

EASD 2021: For persons who have had obesity, returning to a healthy weight may reduce risk for hypertension and dyslipidemia, and modestly for diabetes.

EASD 2021: Women with type 2 diabetes were less likely to meet targets for CV risk management vs men but at lower risk for future CV events, a new study found.

From 2001 to 2017, the estimated prevalence of youth-onset T1D and T2D increased approximately 45% and 95%, respectively, according to a new study.

Finerenone, in patients with mild-to-moderate renal disease and T2D, reduced CV event risk by 13% and risk for a composite renal event by 23%, study authors reported at ESC 2021.

Empagliflozin in patients with HFpEF reduced by 21% the risk of cardiovascular death or heart failure hospitalization across all prespecified subgroups, including those with/without diabetes.

The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.

Citing data that show the incidence of type 2 diabetes increases at age 35 years, the Task Force now recommends the younger age to initiate screening vs the current age of 40 years.